The U.S. government has initiated investigations into the national security risks posed by the import of semiconductors and pharmaceuticals. These investigations could lead to tariffs or other restrictions designed to bolster domestic production of critical technologies and healthcare products.
On April 14, the Department of Commerce announced in the Federal Register that it had launched two separate investigations under Section 232 of the Trade Expansion Act. This legislation grants the president the authority to impose import restrictions if certain products are deemed a threat to national security.
The semiconductor-related investigation will examine a wide range of items, including semiconductor substrates and bare wafers, legacy and advanced semiconductors, microelectronics, and components of semiconductor manufacturing equipment. It will also evaluate derivative products—such as electronic devices that incorporate semiconductors—highlighting the potentially broad scope of the review.
The pharmaceutical investigation, similarly, will focus on finished drugs, essential raw materials like active pharmaceutical ingredients (APIs), and medical countermeasures, including vaccines and antibiotics. The investigation aims to assess vulnerabilities in the pharmaceutical supply chain, especially concerning public health crises.
President Donald Trump has strongly advocated for reducing foreign dependence on key sectors like semiconductors and pharmaceuticals. Citing national security concerns, he has threatened tariffs as a tool to incentivize domestic manufacturing. Under his administration, Section 232 has already been used to impose 25% tariffs on steel, aluminium, and various automotive products.
Given this precedent, there is a high probability that these new investigations could lead to similar tariffs or import quotas. According to the Federal Register, both investigations officially began on April 1, and a formal notice will be published on April 16, after which the Department of Commerce will collect public comments for 21 days.
For semiconductors, the Department is soliciting input on issues across the entire supply chain, including U.S. demand, domestic production capacity, foreign subsidies, state-backed overproduction, export controls, and the necessity of trade barriers like tariffs or quotas.
For pharmaceuticals, public input is being sought on supply chain vulnerabilities, unfair trade practices, and the potential for foreign governments to weaponize pharmaceutical exports during crises.
Once the investigations are underway, the Secretary of Commerce has 270 days to deliver a report to the president, outlining whether the imports in question pose a threat and recommending potential remedies. The president must then decide within 90 days whether to act on those recommendations.
Although the process could take up to a year, the Trump administration appears to be moving quickly. Secretary of Commerce Howard Rutnick stated in an interview that semiconductor tariffs could be announced “probably within a month or two.”